TP53 and neoplasm: Our findings indicate that specific genetic alterations and immune infiltration patterns—particularly the interplay between NK cell populations and tumor TP53 status in HGSOC, as well as diverse genetic aberrations in non-HGSOC—are strongly associated with therapy outcomes.